SOLICITATION NOTICE
Q -- Q-Extraction of DNA
- Notice Date
- 9/4/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20128-NQ
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- Total Small Business
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Prevention Studies Branch (CPSB), plans to enter into a sole source contract with BioServe Biotechnologies, LTD, 1050 West Street, Laurel, MD 20707. The CCR requires the extraction of high molecular weight DNA from human lymphocyte specimens collected in the Polyp prevention Trial (PPT). The ultimate purpose of this research project is to obtain high molecular weight DNA from lymphocytes that are suitable for subsequent analyses and to test the quality of the DNA already extracted from samples. The DNA will be used in future analyses by NCI investigators to investigate the role of different genetic polymorphisms on adenomatous polyp recurrence and diet gene interactions. BioServe Biotechnology is currently in the process of isolating DNA from lymphocytes of 500 polyp prevention trial participants and preparing these and other PPT DNA samples for analysis by custom high-throughput mass-spectrometry based Matrix Assisted Laser Desorption Ionization Time-of-Flight genotyping services for PPT under a separate contract. BioServe Biotechnolgy has previously provided custom high-throughput mass-spectrometry based Matrix Assisted laser Desorption Ionization Time-of-Flight gentoyping services for the PPT. Mass-spectrometry genotyping has provided extremely accurate and reproducible results, with 100% concordance rates in all blinded control samples analyzed. Previously Bioserve performed XRCCi, APE, MTHFR and GSTml assays for the Cancer Prevention Studies Branch(under a separate contract). The CCR has a strong programmatic need to continue the work with Bioserve to maintain the essential scientific comparability of the data especially for samples from the same clinical trial. Bioserve is capable of genotyping 10,000 smaples in 24 hours with almost 100% reproducibility rate, as well as genotype assay with as little as 1-3 nano-grams of genomic DNA. The introduce another compnay would be detrimental to the enormous amount of work already performed. This notice of intent is not a request for competitive quotation, however, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:30 PM EDT on September 19, 2002. This action is pursuant to 41 USC 253(1) and under the authority of FAR 6.302-1. This requirement will be procured as a non-commercial item in accordance with FAR Part 13. Please contact Cynthia Brown, Purchasing Agent 9301) 402-4509 if you have further questions. A determination by the Government not to compete this proposed requirement based upon responese to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collects calls will be accepted. The NAICS Code is: 541380 and the business size standard is $6.0 million.
- Record
- SN00157331-W 20020906/020904213407 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |